Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“Major positive WCLC26 result in relapsed SCLC: TAISHAN-302.
Tambotatug pelitecan (Tam-Peli) vs topotecan:
- OS 13.3 vs 9.4 mo, HR 0.46
- PFS 7.4 vs 2.8 mo, HR 0.29
- ORR 59.1% vs 9.7%
- intracranial response 32% vs 3%
- grade 3+ AEs 55.4% vs 77.9%
My take: a major positive randomized phase 3 trial and a potential new 2L option in SCLC.
Important caveat: this was a China-only study, so broader global validation still matters. Sequencing vs tarlatamab also remains an open question.”
This also can be interesting:
DeLLphi-305: Durvalumab + Tarlatamab Improves Survival in First-Line ES-SCLC
